We are investigating the long-term effects of JR-141 on symptoms of Hunter Syndrome. This study will help us understand its safety and effectiveness for patients with this condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Mucopolysaccharidosis II (Hunter Syndrome) is a rare genetic disorder that results from the body's inability to break down specific sugars, leading to a buildup of these substances in the body. This can cause a range of symptoms affecting various organs and systems.
Hunter Syndrome, also known as Mucopolysaccharidosis II, is a rare genetic disorder characterized by the accumulation of certain sugars in the body, leading to various health issues including joint stiffness and developmental delays.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
